Boston Scientific still expects Axonics deal to close this year, posts Street-beating Q3
Boston Scientific reported third-quarter results that came in ahead of the consensus forecast, raising its 2024 guidance again.
Boston Scientific stock climbs on Q3 sales and earnings beat
Shares of Boston Scientific Corp. rose 1.1% in premarket trades Wednesday after the medical products company reported better-than-expected profit and sales in its third-quarter results, and gave robust earnings guidance.
Boston Sci stock falls 4% amid FARAPULSE study update
Boston Scientific (BSX) shares fell 5% following news that the company has paused a study for its FARAPULSE PFA system due to unforeseen complications. Read more here.
Boston Scientific Q3 Earnings Preview
In this photo illustration, a Boston Scientific Corporation logo seen ... [+] displayed on a smartphone and pc screen in the background. (Photo Illustration
Boston Scientific: Q3 Earnings Snapshot
The average estimate of 12 analysts surveyed by Zacks Investment Research was for earnings of 58 cents per share. The medical device manufacturer posted revenue of $4.21 billion in the period, also exceeding Street forecasts.
Boston Scientific Corporation (BSX) Q3 2024 Earnings Call Transcript
Good morning and welcome to the Boston Scientific Third Quarter 2024 Earnings Call. All participants will be in listen-only mode. [Operator Instructions] After today's presentation, there will be an opportunity to ask questions.
Boston Scientific Corp Q3 Profit Decreases, But Beats Estimates
Boston Scientific Corp (BSX) revealed a profit for third quarter that decreased from last year but beat the Street estimates. The
Boston Scientific Raises Full-Year Guidance After Third-Quarter Beat
Boston Scientific (BSX) raised its 2024 guidance on Wednesday after logging stronger-than-expected growth in third-quarter results. The medical device maker now expects full-year reported revenue growth of 16.
Boston Scientific Q3: Good Growth, But Not Good Enough To Justify Its P/E Ratio
Analysis of Boston Scientific Corporation's Q3 results, future growth projections, and potential impact of regulatory approvals on the stock. Click for more on BSX.
Boston Scientific stock sinks on atrial fibrillation trial pause
Boston Scientific Corp., one of the largest medical device firms in Massachusetts, reported a larger-than-expected increase in its third-quarter net sales on Thursday, but investors pulled back due to a "pause" in a trial of key product in development.
Boston Scientific Profit Falls Even as Demand for Its Heart Products Surges
Key Takeaways Boston Scientific shares fell Wednesday as its third-quarter profit missed estimates.The medical device maker's ...
Boston Scientific Q3 Earnings: Revenue And EPS Beat, Lifts Annual Forecast On Strong Demand For Heart Devices
On Wednesday, Boston Scientific Corporation (NYSE:BSX) reported third-quarter revenues of $4.21 billion, beating the ...
Boston Scientific lifts sales outlook, notes key approval of AFib device with Minnesota ties
The med-tech company with approximately 9,400 employees in Minnesota posted profit and sales that beat Wall Street’s ...
Promising Growth Prospects for Boston Scientific Amid Short-Term Risks and Strategic Acquisitions
Boston Scientific (BSX – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst David ...
Becker's Hospital Review14h
FDA issues critical recalls for Baxter ventilators, Medtronic pumps and Boston Scientific device
The FDA recently announced critical recalls on several widely used medical devices, including Life2000 ventilators, Medtronic's MiniMed insulin pumps and Boston Scientific's Obsidio conformable ...
Five things: Tax compromise, community colleges, Boston Scientific, GE Vernova and the Sacred Cod
Good morning, Boston. Here are the five things you need to know in local business news to start your busy Thursday.
Boston Scientific price target raised to $98 from $95 at RBC Capital
RBC Capital raised the firm’s price target on Boston Scientific (BSX) to $98 from $95 and keeps an Outperform rating on the shares. The ...